Approval of new agents to treat higher risk (HR) myelodysplastic syndrome (MDS) has
stalled since the approval of DNA methyltransferase inhibitors (DNMTi). In addition, the …

Myelodysplastic neoplasm (MDS) is a hematopoietic stem cell disorder that may evolve into
acute myeloid leukemia. Fatal infection is among the most common cause of death in MDS …

Current Treatment Options in Oncology not a clear standard of care. For those without
previous luspatercept exposure it can be considered particularly if there is an SF3B1 …

Simple Summary In patients with hematologic malignancies, especially those undergoing
intensive treatments like chemotherapy, infections pose a significant and life-threatening …

The patterns of low-risk myelodysplastic syndrome (MDS) progression and the clinical and
molecular features of those patterns have not been well described. We divided our low-risk …

Dear Editor, Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal
myeloid disorders characterized by ineffective hematopoiesis and varying degrees of …

Iron overload from repeated transfusions has a negative impact on cardiac function, and iron
chelation therapy may help prevent cardiac dysfunction in transfusion‐dependent patients …

Background and aims: MDS constitute a heterogenous group of myeloid malignancies
mainly characterized by dysfunctional hematopoiesis. Although cytopenia, dysplastic …

Καρδιαγγειακοί βιοδείκτες στα Μυελοδυσπλαστικά σύνδρομα Page 1 1 ΔΗΜΟΚΡΙΤΕΙΟ
ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΡΑΚΗΣ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ ΤΜΗΜΑ ΜΟΡΙΑΚΗΣ ΒΙΟΛΟΓΙΑΣ …

Background Myelodysplastic neoplasms (MDS) present a heightened risk of infections,
contributing significantly to morbidity and mortality. While neutrophil dysfunction is …